Paramount BioSciences, LLC (“Paramount”) is a primary pharmaceutical drug creation and investment organization with its major focus on the medical and life sciences industries. Having Paramount BioCapital, Inc., a FINRA registered broker-dealer in head of funding and raising capital for Portfolio companies, Paramount BioSciences intensely plays a role in the emergence and progression of revolutionary biotechnologies and life sciences.
Paramount BioScienses’ Plan
Not only can Paramount BioSciences offer specialized services and support, but is additionally involved in new product development, biotech organizations purchase and development. It helps the freshly built businesses in several value-adding methods. They will evaluate system candidates for the companies; generate progression strategies to facilitate the growth process prior to, in the course of, as well as following the configuration of Portfolio Firms. Equally, back-up and know-how is fully recognized by BioSciences as it allows its Portfolio Businesses to access to much more experienced infrastructure than they might have. This gives the business management to pay attention to the medicine candidates’ development as opposed to constructing their very own infrastructure. In lots of ways, this kind of design produced by Paramount’s founder Lindsay Rosenwald gives both expert and “back office” support and limits delays in the advancement process, as well as maximized the earnings for Portfolio companies and the client community.
Right after acceptance and in-licensing, a dedicated supervision crew through the complete creation step generally looks after pharmaceutical candidates. Senior medication production personnel at Paramount BioSciences, including Lindsay Rosenwald, facilitate Portfolio Firms in all of the areas of growth. This includes formulation, medical improvement, toxicology, production, quality assurance, and commercialization. Using their extensive working experience in developing top drug solutions, the Paramount’s team provides solutions for an assortment of therapeutically signs, beginning with inflammation to cardiovascular to oncology to neurology and several other hints. Global network of professionals as well as industry frontrunners within the healthcare and research communities provide guidance throughout the candidates’ creation and approval cycle.
Along with an established track record, Paramount BioSciences facilitates Portfolio Corporations hire employees that will guide the new businesses formed around the new compounds. On the list of recent employees at Portfolio Organizations, there are such executives as the previous CEOs of Roche, Biogen, Johnson&Johnson, Amgen and many more.
More than twenty years of financing and progression of biomedical organizations across a wide range of therapeutic indications, Lindsay Rosenwald is head of Paramount BioSciences’ more than 40 biotech organizations. He forms businesses from the ground-up employing his very own cash and then funds are raised from numerous non-public individuals through Paramount Capital.
Paramount handles such important features as human resources, legal, market analysis, economic capabilities. This assists its Portfolio firms to focus on medical research and generating value for shareholders, licensors and patients.
With such a keen eye for locating and constructing progressive medicines, Paramount BioSciences evaluates the quality and promises of drug candidates around the world, from tiny biotech organizations and instructional centres to substantial prescription companies.
Paramount Approach To Value Generation
What makes Paramount BioSciences stand out is that their infrastructure and outer network enables them to help Paramount Incubated Firms right up until they become self-sufficient. The creation period has been developed by Lindsay Rosenwald in 1999 and may be described in a simple pattern much like this one:
Product Property –> Paramount Preliminary Funding and Development –> Incubation –> Portfolio Company Formation –> Cost Inflection Point
Staff for every single Portfolio Business is appointed in agreement with developmental and financial situations. On average, the majorities of workers at Paramount have at least 15 years of experience in biotechnology or medical care industries driving drug applicants through the regulatory and clinical value string. Their expertise ranges from molecular biology to clinical treatments.
With such a serious practical experience across the pharmaceutical creation enterprise, Lindsay Rosenwald has been able to produce the team with leadership roles within the biotech market with numerous pharmaceutical drug products being sold globally, including Viracept, Neulasta, Rituxan, and Kepivance.
Paramount Departments
Paramount Biosciences
With over forty personnel in eight offices globally, Paramount BioSciences compete and bargain for college and business biotechnology entitlements. It develops and in-licenses compounds for numerous restorative signs – from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald helps create standalone biotech corporations that can attract money and succeed as publicly traded firms
Paramount BioCapital, Inc.
Paramount BioCapital Inc. is a NASD-registered dealer that collects capital for the Portfolio Organizations. It raised in excess of $1 billion and around $200 million in 2009. Using their extensive knowledge in investments purchases such as “PIPEs”, reverse takeovers, self-registrations and private placements, Paramount BioCapital is now the leader in the biotechnology capital sector.
Paramount Development
Lindsay Rosenwald operates directly with Paramount Corporate Development, which is involved with in-licensing and narcotic creation activities. The Business Development group contains twenty market veterans with a huge expertise in all facets of pharmaceutical advancement, including formulation, clinical procedures, manufacturing and commercialization.
Paramount BioCapital Asset Management
Property Management is responsible for acquiring and distributing equities of global healthcare organizations. It has an established hedge fund construction and assets under management in numerous private positioning vehicles.
Paramount Acquisition Company
Paramount Acquisition Company creates special equity finance products that match good sized capitals with late-stage non-public firms. It recently declared a $54 million purchase with Valeritas, which is a health-related device business with its principal FDA-approved insulin pump h-Patch.
Paramount BioSciences Executive Management Staff
Normally, Paramount BioSciences workers have got 15 years of strong knowledge in the medical and regulating functions. Headed by Lindsay Rosenwald, the team members participated in a large number of prescription creation and commercialization projects, including Rituxan, Viracept, Sutent, and Neulasta. Far more than 50 compounds presently go through medical development procedure and the products include medicines across a vast range of indications that include neurological diseases, metabolic problems, contagious diseases and cancer.
Lindsay A. Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His considerable expertise within biotechnology, pharmacology and finance made him one of the market leaders in the biotechnology and life sciences industries. With more than 20 years of working experience in building and investing in biotechnology and life science businesses, Dr. Lindsay Rosenwald created and nurtured more than 40 biotech/pharma businesses.
J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His prior practical knowledge includes collaboration at Covington & Burling, where he supplied economic, regulatory, business, and litigation assistance to financial institutions, corporations and individuals.
Benefits of Paramount BioSciences Model
What makes Paramount BioSciences a desired acquirer of drug treatments and developer of biotechnologies is that Lindsay Rosenwald’s team of developers along a global business development team that assesses and facilitates unit and marketplace options. The offices of Paramount BioSciences are situated worldwide, which includes New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising medication candidates are migrated forward rapidly in the certification process. Reps of all areas in drug creation cycle work together to make sure an agreement to move ahead. The next thing is the generation of unit development plans for the compound and hiring supervision personnel. At this time, the chemical substances are usually transferred to Portfolio Companies with no transition hold-up. The product candidates are supported through the specialized medical and regulatory system.
Paramount BioSciences has proved to rapidly perform deals and initiate development work. Its access to money is a crucial part of any product development. It offers Portfolio organizations with the framework that promotes drug candidate’s acceleration through to marketplace, removing odds of program getting stalled.
Clinical and commercial expertise at the company stage assists Paramount Portfolio companies increase value to in-licensed products.
History regarding Financial Wherewithal
Paramount BioSciences under the direction of Lindsay Rosenwald has produced over $1 billion from outside people in addition to their own investment in Paramount’s portfolio organizations. All companies and specialized medical studies funded through the organization get substantial funding on all stages of the creation cycle.
Linsay Rosenwald has regular and close interaction with the leading US sell-side and buy-side organizations that consist of notable health care individuals, with whom Paramount’s hedge funds put money into the deals not directly involving this company by itself. Paramount’s staff has real-time perception of health-related capital markets, which resulted in over $400 million funds for Portfolio Corporations in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences along with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Many of the top health care funds financed in Paramount in 2010, which continues to be a good indication for the development of medical and life sciences industries.